Target Name: UQCRC2
NCBI ID: G7385
Review Report on UQCRC2 Target / Biomarker Content of Review Report on UQCRC2 Target / Biomarker
UQCRC2
Other Name(s): Core protein II | ubiquinol-cytochrome c reductase core protein II | QCR2_HUMAN | UQCR2 | Ubiquinol-Cytochrome c Reductase Core Protein 2 | ubiquinol-cytochrome-c reductase complex core protein 2 | Cytochrome b-c1 complex subunit 2, mitochondrial | Ubiquinol-cytochrome-c reductase complex core protein 2 | MC3DN5 | Ubiquinol-cytochrome c reductase core protein 2 | ubiquinol-cytochrome c reductase core protein 2 | QCR2 | complex III subunit 2 | cytochrome bc-1 complex core protein II | Complex III subunit 2

Unveiling the Potential Drug Target and Biomarker UQCRC2: Unearthing the Power of Proteins

Introduction

Uncovering new drug targets and biomarkers is essential for the development of effective therapies for various diseases. One promising protein known as UQCRC2 (Unique Quotient of Recoverable Cellular Component 2) has recently gained significant attention due to its potential as a drug target and biomarker. In In this article, we will explore the science behind UQCRC2, its potential as a drug target, and its potential as a biomarker for various diseases.

The UQCRC2 Protein

UQCRC2, also known as CD22, is a type of protein that is expressed in various tissues of the body, including the brain, spleen, heart, kidneys, and Peyer's patches in the intestine. It is a glycoprotein with a molecular weight of approximately 180 kDa. Its unique feature is its ability to recycle damaged or dysfunctional cells, which suggests its potential as a therapeutic target for diseases where cell recycling is impaired.

UQCRC2's Potential as a Drug Target

UQCRC2's potential as a drug target is attributed to its unique mechanism of cell recycling. Unlike most proteins, UQCRC2 can survive in damaged cells and participate in the recycling process, which helps to maintain the cell's structure and function. This ability makes UQCRC2 an attractive target for diseases where the recycling of damaged or dysfunctional cells is defective.

One of the key insights into UQCRC2's drug-target potential is its role in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells, which is believed to be caused by the accumulation of damaged or dysfunctional proteins. UQCRC2 has been shown to be highly expressed in the brains of individuals with Alzheimer's disease and has been linked to the progression of the disease. Therefore, UQCRC2 has great potential as a therapeutic target for these conditions.

Another potential drug target for UQCRC2 is its role in cancer. The recycling ability of UQCRC2 has been shown to contribute to the survival of cancer cells, making it an attractive target for cancer therapies. UQCRC2 has been shown to be highly expressed in various types of cancer, including lung, breast, and ovarian cancer. Therefore, UQCRC2 has significant potential as a drug target for cancer therapies.

UQCRC2's Potential as a Biomarker

In addition to its potential as a drug target, UQCRC2 also has significant potential as a biomarker for various diseases. Its unique ability to recycle damaged or dysfunctional cells makes it an attractive target for diagnostic tools that can identify the early stages of disease.

One of the key applications of UQCRC2 as a biomarker is its potential to detect early signs of neurodegenerative diseases, such as Alzheimer's disease. The accumulation of damaged or dysfunctional proteins is a hallmark of neurodegenerative diseases, and UQCRC2 has been shown to be highly expressed in the brains of individuals with Alzheimer's disease. Therefore, UQCRC2 has significant potential as a diagnostic tool for the early detection of neurodegenerative diseases.

UQCRC2's Potential as a Biomarker for other Diseases

UQCRC2 has also been shown to have potential as a biomarker for other diseases, including cancer, cardiovascular disease, and autoimmune disorders. Its unique ability to recycle damaged or dysfunctional cells makes it an attractive target for diagnostic tools that can identify the early stages of disease.

For example, UQCRC2 has been shown to be highly expressed in the tissues of individuals with multiple sclerosis, a condition characterized by the accumulation of damaged proteins in the central nervous system. Therefore, UQCRC2 has significant potential as a diagnostic tool for

Protein Name: Ubiquinol-cytochrome C Reductase Core Protein 2

Functions: Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over the inner membrane that drives transmembrane transport and the ATP synthase. The cytochrome b-c1 complex catalyzes electron transfer from ubiquinol to cytochrome c, linking this redox reaction to translocation of protons across the mitochondrial inner membrane, with protons being carried across the membrane as hydrogens on the quinol. In the process called Q cycle, 2 protons are consumed from the matrix, 4 protons are released into the intermembrane space and 2 electrons are passed to cytochrome c (By similarity). The 2 core subunits UQCRC1/QCR1 and UQCRC2/QCR2 are homologous to the 2 mitochondrial-processing peptidase (MPP) subunits beta-MPP and alpha-MPP respectively, and they seem to have preserved their MPP processing properties (By similarity). May be involved in the in situ processing of UQCRFS1 into the mature Rieske protein and its mitochondrial targeting sequence (MTS)/subunit 9 when incorporated into complex III (Probable)

The "UQCRC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UQCRC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

UQCRC2P1 | UQCRFS1 | UQCRFS1P1 | UQCRH | UQCRHL | UQCRQ | URAD | URAHP | URB1 | URB1-AS1 | URB2 | Urea transporter | URGCP | URGCP-MRPS24 | URI1 | Uridine phosphorylase | URM1 | UROC1 | UROD | UROS | USB1 | USE1 | USF1 | USF2 | USF3 | USH1C | USH1G | USH2A | USHBP1 | USO1 | USP1 | USP1-UAF1 complex | USP10 | USP11 | USP12 | USP12-AS1 | USP12-DT | USP13 | USP14 | USP15 | USP16 | USP17L1 | USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44